TESARO and AnaptysBio collaborate on immuno-oncology antibody program TESARO and AnaptysBio announced a strategic immuno-oncology collaboration under which AnaptysBio has granted TESARO exclusive rights to antibody programs targeting PD-1, TIM-3 and LAG-3, including monospecific and dual reactive antibody drug candidates. Antibody candidates from these programs are expected to enter clinical trials over the next 18 to 24 months. TESARO will pay an upfront license fee of $17M and provide funding of costs incurred by AnaptysBio related to the development programs. For each development program, AnaptysBio is eligible to receive milestone payments associated with certain U.S. and ex-U.S. regulatory submissions and approvals in multiple indications. AnaptysBio and TESARO will together complete preclinical development of the antibody candidates, with TESARO being solely responsible for all clinical development, manufacturing, regulatory and commercial activities.